KAJ70103
Colorimetric
Plasma, Serum
Quantitative
156.25 - 10,000 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
MSB-0010718C,MSB0010682,M7824,MSB0010718C, bintrafusp alfa, CAS: 1537032-82-8
Avelumab maintenance in advanced urothelial carcinoma: real-world data from Northern Spain (AVEBLADDER study)., PMID:40514610
Avelumab plus axitinib in patients with advanced gastrointestinal stromal tumor., PMID:40499273
Validation of a 15-Gene Prognostic Signature in Metastatic Clear Cell Renal Cell Carcinoma., PMID:40479621
Clinical features, treatment, and outcomes of anti-PD-L1 induced psoriasis., PMID:40474015
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease., PMID:40467365
Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis., PMID:40456670
Avelumab and taxol chemotherapy in platinum-refractory or ineligible metastatic urothelial carcinoma (AVETAX trial)., PMID:40451703
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma., PMID:40448574
A case of irAE myositis with positive anti-striational antibodies after anti-PD-L1 antibody administration: a case report., PMID:40445182
Avelumab-Induced Ocular Myasthenia Gravis: A Case Report., PMID:40416255
Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial., PMID:40413024
Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1., PMID:40411581
Interplay between pharmacokinetics and immunogenicity of therapeutic proteins: stepwise development of a bidirectional joint pharmacokinetics-anti-drug antibodies model., PMID:40399699
Comment on "Phase I/II Trial of Perioperative Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Junction Cancer"., PMID:40396495
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer., PMID:40393272
Phase II study of perioperative Avelumab plus chemotherapy for patients with resectable gastric cancer or gastroesophageal junction cancer - the MONEO Study., PMID:40388549
A Cost-Effectiveness Analysis for Avelumab as a First-Line Maintenance Treatment of Advanced Urothelial Carcinoma in the Netherlands., PMID:40381164
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes., PMID:40378559
Evaluation of Optimal Sequential Treatment Patterns and Clinical Outcomes in Patients With Advanced Urothelial Carcinoma Treated With First-Line Platinum-Based Chemotherapy: A Multicenter Collaborative Study., PMID:40375459
Additional immunotherapy to standard of care for unresectable locally advanced head and neck squamous cell carcinoma: a meta-analysis., PMID:40373754
Autoencoder techniques for survival analysis on renal cell carcinoma., PMID:40373089
Editorial Comment to "Serum Lactate Dehydrogenase Level Prior to First-Line Chemotherapy for Metastatic Urothelial Carcinoma is a Prognostic Factor for Avelumab Maintenance Therapy: A Multicenter Retrospective Study"., PMID:40371448
Association of Sinonasal Symptoms and Disease With Immune Checkpoint Inhibitor Therapy., PMID:40370338
Immune Checkpoint Inhibitors and Antibody-Drug Conjugates in Urothelial Carcinoma: Current Landscape and Future Directions., PMID:40361519
Haematological toxicities with immune checkpoint inhibitors in digestive system tumors: a systematic review and network meta-analysis of randomized controlled trials., PMID:40360867
Co-Occurrence of Hypophysitis and Thyroiditis Induced by PD-L1 Inhibitor Avelumab: Clinical Insights., PMID:40356788
Accelerated atherosclerosis associated with immune checkpoint inhibitors: a systematic review and meta-analysis of pre-clinical studies., PMID:40354680
Complete Response after Avelumab Maintenance Therapy: Successful Management of Metastatic Urothelial Carcinoma., PMID:40352709
A Case of Immune-Related Adverse Events, Including Myasthenia Gravis, Myositis, and Myocarditis, during Avelumab and Axitinib Combination Therapy., PMID:40351546
Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study., PMID:40351326
Serum Lactate Dehydrogenase Level Prior to First-Line Chemotherapy for Metastatic Urothelial Carcinoma Is a Prognostic Factor for Avelumab Maintenance Therapy: A Multicenter Retrospective Study., PMID:40329662
Efficacy of First-Line Treatments for Advanced Renal Cell Carcinoma: A Bayesian Network Meta-analysis of Objective Response, Progression-Free Survival, and Overall Survival., PMID:40329046
Liver transplantation for hepatocellular carcinoma following immunotherapy., PMID:40326429
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial., PMID:40318950
Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab., PMID:40311014
A Phase II Randomized Study of Paclitaxel alone or combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor Positive Breast Cancer: the BRACELET-01/PrE0113 study., PMID:40300087
A Real-World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Avelumab., PMID:40291233
Pharmacovigilance study on the reporting frequency of atrial fibrillation with immune checkpoint inhibitors: insights from FDA Adverse Event Reporting System., PMID:40290514
Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced microsatellite stable rectal adenocarcinoma: The Averectal study., PMID:40286473
Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study., PMID:40277744
Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial)., PMID:40244420
Grade 3 and Grade 4 Cutaneous toxicities in patients across multiple solid tumour types receiving checkpoint inhibitor therapy: An observational study. The experience of a single large specialist institution., PMID:40241399
Phase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: The role of M2 macrophage landscape in predicting response., PMID:40239627
Assessment of Immunoscore, MRI Tumor Regression Grade, and Neoadjuvant Rectal Score in Predicting Pathologic Response in Locally Advanced Rectal Cancer in the Averectal Study., PMID:40218263
Immune check point inhibitors for ocular adnexal and periocular tumors., PMID:40213294
Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis., PMID:40204996
Real-world avelumab first-line maintenance in advanced urothelial carcinoma: systematic review and meta-analysis., PMID:40184226
Prediction, prevention, and precision treatment of immune checkpoint inhibitor neurological toxicity using autoantibodies, cytokines, and microbiota., PMID:40181971
Cisplatin-induced therapy-related myelodysplastic syndrome during avelumab maintenance therapy for metastatic urothelial carcinoma., PMID:40160873
A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies., PMID:40139261
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
